New York State Contract Reporter #26-164

Roswell Park Cancer Institute Corp. is seeking proposals for the procurement of ultra-high-throughput Next Generation Sequencer (NGS) systems and related products and services for its Genomics Shared Resource and Advanced Molecular Diagnostics departments. - Government Buyer: - Roswell Park Cancer Institute Corp. (Supply Chain Management division) - Also referenced as Roswell Park Comprehensive Cancer Center - OEMs and Vendors: - Illumina Inc. is specifically highlighted as a relevant OEM, with multiple Illumina devices listed and prior contracts noted - Products/Services Requested: - Ultra-high-throughput NGS systems supporting whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted panels, and RNA sequencing - Specific Illumina devices requested include: - NextSeq 1000 Sequencing System - MiSeq DNA sequencer (quantity: 2) - NextSeq 500/550Dx System - NextSeq 2000 Sequencer (quantity: 2) - Infinium Automated Pipetting System with IAC - iScan System - Related reagents and consumables compatible with the NGS systems - Support and maintenance services, including 5-year consumable and maintenance pricing for existing and new Illumina devices - Unique or Notable Requirements: - Emphasis on throughput, data quality, reproducibility, scalability, and operational efficiency - Bidders are encouraged to propose all qualifying devices in their product lineup - Potential trade-in of an existing Illumina NovaSeq 6000 - Compliance with Equal Employment Opportunity (EEO) policies, non-collusion affidavits, disclosure forms, and Roswell Park's required clauses - No set-aside restrictions; open to all qualified vendors - Place of Performance/Delivery: - Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263

Roswell Park Cancer Institute Corp. is soliciting proposals for a Next Generation Sequencer (NGS) system to be used in their Genomics Shared Resource and Advanced Molecular Diagnostics departments. The system should support high-volume sequencing applications such as whole-genome sequencing, whole-exome sequencing, targeted panels, and RNA sequencing, emphasizing throughput, data quality, reproducibility, scalability, and operational efficiency. The contract term is 5-10 years, and the solicitation includes related reagents, consumables, and support services. Proposals are due by April 14, 2026.